Lidocaine Baxter (Lidocaine Hydrochloride)

Lidocaine Baxter is a local anesthetic and anti‑arrhythmic that acts on sodium channels in nerve and cardiac tissue.

• Local anesthesia: produces reversible loss of sensation for minor surgical, dental or diagnostic procedures.
• Ventricular arrhythmias: suppresses life‑threatening ventricular tachycardia when administered intravenously.
• Cardiac electrophysiology: facilitates intra‑arterial or intracoronary mapping during interventional procedures.

• Lidocaine Hydrochloride blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, stabilising the inactive state of the channel. This inhibition prevents rapid depolarisation, thereby halting the propagation of nerve impulses and reducing abnormal cardiac excitability. The effect is dose‑dependent and reversible, providing localized anaesthesia and anti‑arrhythmic activity.

Adverse reactions may vary with dose, route and patient factors.

Common Side Effects

• Dizziness or light‑headedness
• Metallic taste in the mouth
• Tingling or numbness around the injection site
• Transient visual disturbances
• Mild hypotension
• Nausea or vomiting

Serious or Rare Side Effects

• Cardiac arrest or severe bradyarrhythmia
• Convulsions or central nervous system depression
• Allergic reactions including anaphylaxis
• Methemoglobinemia
• Persistent ventricular arrhythmias despite therapy
• Severe hypotension unresponsive to fluids

Lidocaine Baxter requires careful clinical monitoring and patient assessment.

• Cardiac monitoring: observe ECG and blood pressure continuously during IV administration.
• Allergy assessment: avoid use in patients with known lidocaine hypersensitivity.
• Hepatic impairment: reduce dose or increase monitoring due to decreased metabolism.
• Administration rate: avoid rapid bolus injection to minimise CNS toxicity.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lidocaine may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiotoxicity.
• Beta‑blockers: may enhance bradycardia and hypotension.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., carbamazepine, phenobarbital): may reduce lidocaine efficacy.
• Loop diuretics: can alter plasma lidocaine levels.
• General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression.